A nurse working in an urgent care clinic is collecting data from a client who takes montelukast. Which of the following is an expected therapeutic effect of this medication?

D. The expected therapeutic effect of montelukast is the reduction of bronchial inflammation. By blocking leukotriene receptors, montelukast helps to prevent the constriction of airway muscles, decrease mucus secretion, and reduce inflammation in the airways. This can lead to improved asthma control and symptom management. A. Montelukast is not indicated for the treatment of gastric acid-related conditions such as gastroesophageal reflux disease (GERD) or peptic ulcers. B. Montelukast is not typically associated with peripheral vasodilation. Its primary mechanism of action involves blocking the action of leukotrienes, which are inflammatory mediators involved in allergic and asthmatic reactions. C. Montelukast does not affect white blood cell (WBC) count.